Treatment of invasive fungal infections in clinical practice: A multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole

International Journal of Hematology

Volumn 87, Issue 2, 2008, Pages 126-131

  Vehreschild, Jörg J ^a   Böhme, Angelika ^b   Reichert, Dietmar ^c   Kiehl, Michael G ^d   Arenz, Dorothee ^a   Pankraz, Karen ^a   Kochanek, Matthias ^a   Ullmann, Andrew J ^e   Cornely, Oliver A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c KLINIKUM OLDENBURG   (Germany)

^d SP Pneumologie Intensiv und Schlafmedizin   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Antifungals; Aspergillosis; Candidiasis; Drug therapy; Fungal infection; Prophylaxis; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; VORICONAZOLE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EDEMA; FEMALE; HALLUCINATION; HEALTH SURVEY; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NAUSEA; RASH; VISUAL DISORDER; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYCOSES; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 42049084636     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0045-z     Document Type: Article

References (25)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26(4):781-803; quiz 4-5.
2. Klimowski LL, Rotstein C, Cummings KM. Incidence of nosocomial aspergillosis in patients with leukemia over a 20-year period. Infect Control Hosp Epidemiol. 1989;10(7):299-305.
3. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis. 1999;28(2):331-40.
4. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993;118(7):495-503.
5. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol. 2003;41(1):78-83.
6. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother. 1998;42(12):3242-4.
7. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis. 2004;48(3):201-5.
8. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1998;42(6):741-5.
9. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother. 1998;42(11):3018-21.
10. Linares MJ, Charriel G, Solis F, Rodriguez F, Ibarra A, Casal M. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods. J Clin Microbiol. 2005;43(1):250-3.
11. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol. 1999;37(12):3946-51.
12. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109, 496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol. 1998;36(1):198-202.
13. Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis. 1998;17(8):573-5.
14. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 2001;39(3):954-8.
15. Gonzalez GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol. 2005;43(3):281-4.
16. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15.
17. Pfizer Inc. N. label information: VFEND (voriconazole). New York: Pfizer Inc.; 2006.
18. Bohme A, Ruhnke M, Buchheidt D, Karthaus M, Einsele H, Guth S, et al. Treatment of fungal infections in hematology and oncology-guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and oncology (DGHO). Ann Hematol. 2003;82(Suppl 2):S133-40.
19. NCI, DCTD, NIH, DHHS. Common toxicity criteria version 2.0. Bethesda: National Institutes of Health; 1999.
20. Cornely OA, Maertens J, Bresnik M, Herbrecht R. Liposomal amphotericin B as initial therapy for invasive filamentous fungal infections: a randomized, prospective trial of a high loading regimen versus a standard dosing (AmBiLOAD Trial). Blood. 2005;106(11):900a.
21. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7-14.
22. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346(4):225-34.
23. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42(10):1417-727.
24. Ferns RB. Evaluation of the role of real-time PCR in the diagnosis of invasive aspergillosis. Leuk Lymphoma. 2006;47(1):15-20.
25. Karthaus M, Cornely OA. Recent developments in the management of invasive fungal infections in patients with hematological malignancies. Ann Hematol. 2005;84(4):207-16.